Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$5.67 USD
-0.41 (-6.74%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $5.67 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TERN 5.67 -0.41(-6.74%)
Will TERN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TERN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TERN
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
TERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
Other News for TERN
Terns Pharma (TERN) Projects Financial Stability Until 2028 with Ongoing Trials
Terns Pharmaceuticals GAAP EPS of -$0.26 beats by $0.03
Terns Pharmaceuticals reports Q2 EPS (26c), consensus (29c)
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule ...
Commit To Buy Terns Pharmaceuticals At $3, Earn 23.3% Using Options